| DRD2 — Dopamine Receptor D2 | |
|---|---|
| Symbol | DRD2 |
| Full Name | Dopamine Receptor D2 |
| Chromosome | 11q23.2 |
| NCBI Gene | 1819 |
| Ensembl | ENSG00000149295 |
| UniProt | P14416 |
| Diseases | Parkinson's Disease, Schizophrenia, Parkinsonism |
| Expression | Striatum, Substantia nigra, Pituitary, Cortex |
Drd2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
DRD2 (Dopamine Receptor D2) encodes the D2 dopamine receptor, a G protein-coupled receptor that inhibits adenylyl cyclase and reduces intracellular cAMP. It functions as both a presynaptic autoreceptor and postsynaptic receptor, critical for motor control, reward, and prolactin regulation[1].
D2 receptors are the primary therapeutic target for PD motor symptoms. Several drug classes target D2 receptors:
Most antipsychotics work by blocking D2 receptors:
D2 agonists are first-line treatment for RLS
The D2 receptor couples to Gi/o proteins, leading to:
D2 receptors can signal through beta-arrestin independently of G proteins, which may contribute to:
The study of Drd2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011;63(1):182-217. PMID:21303898 ↩︎